scholarly article | Q13442814 |
P356 | DOI | 10.1007/S00415-007-4007-9 |
P2093 | author name string | David J. Brooks | |
Ariel Gordin | |||
P2860 | cites work | COMT inhibitors in Parkinson's disease: can they prevent and/or reverse levodopa-induced motor complications? | Q35626734 |
The effect of entacapone (OR-611) on brain [18F]-6-L-fluorodopa metabolism: implications for levodopa therapy of Parkinson's disease | Q39112092 | ||
Cost-effectiveness analysis of entacapone in Parkinson's disease: a Markov process analysis | Q43797164 | ||
COMT genotype and effectiveness of entacapone in patients with fluctuating Parkinson's disease | Q43896022 | ||
Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients | Q48125712 | ||
Levodopa in Parkinsonism: Potentiation of Central Effects with a Peripheral Inhibitor | Q51107835 | ||
Entacapone in combination with standard or controlled-release levodopa/carbidopa: a clinical and pharmacokinetic study in patients with Parkinson's disease. | Q54002951 | ||
P433 | issue | S4 | |
P921 | main subject | Parkinson's disease | Q11085 |
pharmacology | Q128406 | ||
P304 | page(s) | IV37-IV48 | |
P577 | publication date | 2007-08-01 | |
P1433 | published in | Journal of Neurology | Q6295649 |
P1476 | title | Clinical pharmacology and therapeutic use of COMT inhibition in Parkinson's disease | |
P478 | volume | 254 |
Q45934197 | Levodopa/carbidopa/entacapone in Parkinson's disease. | cites work | P2860 |
Search more.